No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
dactinomycin Sensitive: A1 - Approval
|
dactinomycin Sensitive: A1 - Approval
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
IE Sensitive: A2 - Guideline
|
IE Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
VC Sensitive: A2 - Guideline
|
VC Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
GT Sensitive: A2 - Guideline
|
GT Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
melphalan + busulfan Sensitive: A2 - Guideline
|
melphalan + busulfan Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
ifosfamide + cyclophosphamide + etoposide IV + topotecan Sensitive: A2 - Guideline
|
ifosfamide + cyclophosphamide + etoposide IV + topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
temozolomide + irinotecan Sensitive: A2 - Guideline
|
temozolomide + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline
|
temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
cyclophosphamide + topotecan Sensitive: A2 - Guideline
|
cyclophosphamide + topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline
|
carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
gemcitabine + docetaxel Sensitive: A2 - Guideline
|
gemcitabine + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
cabozantinib tablet Sensitive: A2 - Guideline
|
cabozantinib tablet Sensitive: A2 - Guideline
|
TMB-H
|
Ewing Sarcoma
|
TMB-H
|
Ewing Sarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Ewing Sarcoma
|
MSI-H/dMMR
|
Ewing Sarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
VIDE Sensitive: A2 - Guideline
|
VIDE Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
VAI Sensitive: A2 - Guideline
|
VAI Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
VDC Sensitive: A2 - Guideline
|
VDC Sensitive: A2 - Guideline
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
SP2577 Sensitive: B - Late Trials
|
SP2577 Sensitive: B - Late Trials
|
No biomarker
|
Ewing Sarcoma
|
No biomarker
|
Ewing Sarcoma
|
ONCT-216 Sensitive: B - Late Trials
|
ONCT-216 Sensitive: B - Late Trials
|
MGMT promoter methylation
|
Ewing Sarcoma
|
MGMT promoter methylation
|
Ewing Sarcoma
|
temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria
|
temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria
|
IGF1R underexpression
|
Ewing Sarcoma
|
IGF1R underexpression
|
Ewing Sarcoma
|
mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials
|
mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials
|
IGF1 elevation
|
Ewing Sarcoma
|
IGF1 elevation
|
Ewing Sarcoma
|
CP-751,871 Sensitive: C3 – Early Trials
|
CP-751,871 Sensitive: C3 – Early Trials
|
PTPRD R995C
|
Ewing Sarcoma
|
PTPRD R995C
|
Ewing Sarcoma
|
mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials
|
mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials
|
PTPRD V253I + PTPRD W775stop
|
Ewing Sarcoma
|
PTPRD V253I + PTPRD W775stop
|
Ewing Sarcoma
|
mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials
|
mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials
|
PTPRD V253I + PTPRD W775stop
|
Ewing Sarcoma
|
PTPRD V253I + PTPRD W775stop
|
Ewing Sarcoma
|
IGF-1R inhibitor Sensitive: C3 – Early Trials
|
IGF-1R inhibitor Sensitive: C3 – Early Trials
|
SPARC overexpression
|
Ewing Sarcoma
|
SPARC overexpression
|
Ewing Sarcoma
|
albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
B4GALNT1 expression
|
Ewing Sarcoma
|
B4GALNT1 expression
|
Ewing Sarcoma
|
dinutuximab beta Sensitive: C3 – Early Trials
|
dinutuximab beta Sensitive: C3 – Early Trials
|
EWSR1-FLI1 fusion
|
Ewing Sarcoma
|
EWSR1-FLI1 fusion
|
Ewing Sarcoma
|
VDC Sensitive: C4 – Case Studies
|
VDC Sensitive: C4 – Case Studies
|
FGFR3 amplification + FGFR4 amplification + FLT4 amplification
|
Ewing Sarcoma
|
FGFR3 amplification + FGFR4 amplification + FLT4 amplification
|
Ewing Sarcoma
|
trametinib + pazopanib Resistant: C4 – Case Studies
|
trametinib + pazopanib Resistant: C4 – Case Studies
|
CD99 positive + VIM positive
|
Ewing Sarcoma
|
CD99 positive + VIM positive
|
Ewing Sarcoma
|
OPEC Sensitive: C4 – Case Studies
|
OPEC Sensitive: C4 – Case Studies
|
IGF1R expression
|
Ewing Sarcoma
|
IGF1R expression
|
Ewing Sarcoma
|
IGF-1R inhibitor Sensitive: D – Preclinical
|
IGF-1R inhibitor Sensitive: D – Preclinical
|
EWSR1-FLI1 fusion
|
Ewing Sarcoma
|
EWSR1-FLI1 fusion
|
Ewing Sarcoma
|
CDK12 inhibitor Sensitive: D – Preclinical
|
CDK12 inhibitor Sensitive: D – Preclinical
|
FUS-ERG fusion
|
Ewing Sarcoma
|
FUS-ERG fusion
|
Ewing Sarcoma
|
ASP7487 Sensitive: D – Preclinical
|
ASP7487 Sensitive: D – Preclinical
|
CDKN2A deletion
|
Ewing Sarcoma
|
CDKN2A deletion
|
Ewing Sarcoma
|
ASP7487 Sensitive: D – Preclinical
|
ASP7487 Sensitive: D – Preclinical
|
PAK4 deletion
|
Ewing Sarcoma
|
PAK4 deletion
|
Ewing Sarcoma
|
ASP7487 Sensitive: D – Preclinical
|
ASP7487 Sensitive: D – Preclinical
|
FUS-ERG fusion
|
Ewing Sarcoma
|
FUS-ERG fusion
|
Ewing Sarcoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
PAK4 deletion
|
Ewing Sarcoma
|
PAK4 deletion
|
Ewing Sarcoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
CDKN2A deletion
|
Ewing Sarcoma
|
CDKN2A deletion
|
Ewing Sarcoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
CASP8 overexpression
|
Ewing Sarcoma
|
CASP8 overexpression
|
Ewing Sarcoma
|
AMG 655 Sensitive: D – Preclinical
|
AMG 655 Sensitive: D – Preclinical
|
KDM1A overexpression
|
Ewing Sarcoma
|
KDM1A overexpression
|
Ewing Sarcoma
|
SP2577 Sensitive: D – Preclinical
|
SP2577 Sensitive: D – Preclinical
|